Cargando…
LDL-C: lower is better for longer—even at low risk
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) causes atherosclerotic disease, as demonstrated in experimental and epidemiological cohorts, randomised controlled trials, and Mendelian randomisation studies. MAIN TEXT: There is considerable inconsistency between existing guidelines as to how...
Autores principales: | Penson, Peter E., Pirro, Matteo, Banach, Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545575/ https://www.ncbi.nlm.nih.gov/pubmed/33032586 http://dx.doi.org/10.1186/s12916-020-01792-7 |
Ejemplares similares
-
Trustworthy guidelines – excellent; customized care tools – even better
por: Elwyn, Glyn, et al.
Publicado: (2015) -
The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020) -
Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012) -
Implications of the obesity epidemic for lipid-lowering therapy: Non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target
por: Hoenig, Michel R
Publicado: (2008) -
Don’t abandon RCTs in IVF. We don’t even understand them
por: Wilkinson, J, et al.
Publicado: (2019)